Provectus Completes Patient Enrollment In Phase 2 Atopic Dermatitis Trial

Published: 01-Jul-2009

PH-10, a topical drug for treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition

Provectus has completed patient enrollment for its Phase 2 study of PH-10 for atopic dermatitis. PH-10 is a topical drug for the treatment of dermatologic diseases, including atopic dermatitis, a chronic skin condition that includes some forms of eczema.

The Phase 2 study was designed to evaluate safety and efficacy of PH-10 in at least twenty subjects with mild to severe forms of the disease.

Craig Dees, CEO of Provectus said: Very preliminary analysis of efficacy data from the first 5 subjects to complete the study showed that all experienced improvement, while safety data from the first fourteen subjects showed the treatment to be well tolerated. Although it will be several months before data from all study subjects is collected and analyzed, these initial results are extremely encouraging.

Having reached this milestone for atopic dermatitis, our next steps are to either seek a licensing partner for PH-10, or partner with a pharmaceutical dermatology concern to co-develop the product,” he added.

No items to display

Tell your friend about this article